The Oncology Institute, Inc. TOI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $813K+5.3% | $772K+62.9% | $474K-61.1% | $1.22M-31.3% | $1.77M-11.0% | |
| Patient services | $4.25M-26.2% | $5.76M+38.2% | $4.17M+28.0% | $3.26M-27.9% | $4.52M+92.6% | |
| Specialty pharmacy | $16.8M— | —— | —— | —— | $9.4M+31.6% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $26.93M+14.3% | $23.57M+14.6% | $20.57M+9.2% | $18.84M+7.7% | $17.5M-0.1% | |
| Clinical trials & other | $813K+15.3% | $705K+48.7% | $474K-64.6% | $1.34M-34.6% | $2.05M-17.0% | |
| FFS revenue | $32.16M-11.3% | $36.27M-8.5% | $39.62M+6.9% | $37.05M+4.1% | $35.57M+8.7% | |
| Patient services | $59.09M-1.3% | $59.84M-0.6% | $60.2M+7.7% | $55.89M+5.3% | $53.07M+5.7% | |
| Specialty Pharmacy | $87.54M— | —— | —— | —— | $49.29M+9.6% | |
| Number of lease modifications by Geography | ||||||
| CALIFORNIA | 1— | —— | —— | —— | —— | |
| FLORIDA | 4— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
